Streptokinase detailed information

Streptokinase detailed information

Clinical data
Routes of administration	IV
ATC code	B01AD01 (WHO) B06AA55 (WHO)
Legal status
Legal status	Legal in most countries
Pharmacokinetic data
Elimination half-life	approximately 20 minutes
Identifiers
IUPAC name Streptococci streptokinase
CAS Number	9002-01-1
DrugBank	BTD00028
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C2100H3278N566O669S4
Molar mass	47286.7 g/mol

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Streptokinase is an extracellular metallo-enzyme produced by beta-haemolytic streptococcus and is used as an effective and cheap clot-dissolving medication in some cases of myocardial infarction (heart attack) and pulmonary embolism.

It belongs to a group of medications known as fibrinolytics, and works by activating plasminogen through cleavage to produce plasmin.

The half life of streptokinase is approximately 20 minutes (quoted in SPC).

Mechanism of Action

Plasmin is produced in the blood to break down the major constituent of blood clots fibrin, therefore dissolving clots once they have fulfilled their purpose in stopping bleeding. Extra production of plasmin caused by streptokinase breaks down unwanted blood clots, for example, in the lungs (pulmonary embolism).

Administration

It is given intravenously as soon as possible after the onset of a heart attack (acute phase - myocardial infarction) to dissolve clots in the arteries of the heart wall. This reduces the amount of damage to the heart muscle. Streptokinase is a bacterial product so the body will build up an immunity to it. It is recommended that this medication should not be used again after four days from the first administration, as it may not be as effective and can also cause an allergic reaction. For this reason, it is usually given only for a person's first heart attack. Overdose of Streptokinase or tPA can be treated with Aminocaproic acid.

Marketing

It is marketed in Chile as Streptase by Alpes Selection, under license of ZLB Behring from Marburg, Germany.

External links

• Streptokinase at the US National Library of Medicine Medical Subject Headings (MeSH)

de:Streptokinase

Template:WikiDoc Sources